(Q33720568)

28 July 2017

1 reference

title

Hepatitis C virus: current understanding and prospects for future therapies (English)

1 reference

28 July 2017

1 reference

Rosen HR

1

1 reference

28 July 2017

Gretch DR

series ordinal

2

1 reference

28 July 2017

publication date

1 September 1999

1 reference

Trends in Molecular Medicine

28 July 2017

published in

1 reference

28 July 2017

volume

5

1 reference

28 July 2017

issue

9

1 reference

28 July 2017

page(s)

393-399

1 reference

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1B.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Interactions between alcohol and hepatitis viruses in the liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Acquisition of hepatitis C by a conjunctival splash

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Correlates of hepatitis C virus infections among injection drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Virology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Use and interpretation of HCV diagnostic tests in the clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

The interferon sensitivity determining region: all hepatitis C virus isolates are not the same

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Characterization of Kunjin virus RNA-dependent RNA polymerase: reinitiation of synthesis in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Binding of hepatitis C virus to CD81

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Specific regulation of gene expression by antisense, sense and antigene nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Ribozymes in gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Targeting the Achilles' heel of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901523-3

7 January 2021

10.1016/S1357-4310(99)01523-3

Identifiers

DOI

1 reference

28 July 2017

1 reference